NCT03430661View on ClinicalTrials.gov

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

May 20, 2019

Study Completion Date

May 29, 2019

Conditions
Healthy
Interventions
DRUG

ACT-246475

Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection

DRUG

Clopidogrel

Tablet for oral administration (300 or 600 mg)

DRUG

Prasugrel

Tablet for oral administration (60 mg)

DRUG

Placebo

Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution

DRUG

Ticagrelor

Tablet for oral administration (180 mg)

Trial Locations (1)

07103

Biotrial Inc, Newark

All Listed Sponsors
lead

Viatris Innovation GmbH

INDUSTRY

NCT03430661 - A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects | Biotech Hunter | Biotech Hunter